PATENT CLAIM ANALYSIS

Application Number: 16220267
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "284000"]

Abstract:
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Claim (Index 2):
The compound of  claim 1 , wherein A and X are each independently selected from the following by removal of one hydrogen atom: wherein each of the above shown aryl and heteroaryl groups is optionally substituted when possible and may be connected to the dihydropyrimidine core through a carbon.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 98.0
- Lexical Diversity: 1.72131
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16210472', '15209150', '15421777', '15617445', '15216124']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8155090246123562
- 35 USC 102 Novelty (BERT): 0.5447987027305192
- Combined Prediction Score: 0.7884379924241725
- Mean Citation Score: 371.363898
- Max Citation Score: 383.03064
- Similarity Product: 366.98958633439065

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test